2024
Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx).
Liu Y, Ma Z, Moreira A, Chachoua A, Velcheti V, Lau S, Punekar S, Sabari J, Shum E. Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx). Journal Of Clinical Oncology 2024, 42: e20597-e20597. DOI: 10.1200/jco.2024.42.16_suppl.e20597.Peer-Reviewed Original ResearchNon-small-cell lung cancerTyrosine kinase inhibitorsStage IV non-small-cell lung cancerIV non-small-cell lung cancerOverall survivalCox proportional-hazards modelRetrospective studyProportional-hazards modelMedian OSMetastatic non-small-cell lung cancerHazard ratioIRB-approved retrospective studyMultivariate Cox proportional-hazards modelProgression-free survivalYears of follow-upKaplan-Meier methodLog-rank testAssess survival differencesCalculate hazard ratiosFLAURA trialL858R patientsNSCLC ptsSequential afatinibSuperior OSEGFR mutations
2020
Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.
Cytryn S, Punekar S, Tenet M, Ullah T, Wang B, Goldberg J, Velcheti V, Wong K, Chachoua A, Shum E, Sabari J. Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib. Journal Of Clinical Oncology 2020, 38: e21679-e21679. DOI: 10.1200/jco.2020.38.15_suppl.e21679.Peer-Reviewed Original ResearchNon-small cell lung cancerGeneration TKIsAdvanced diseaseSuperior PFSDe novo stage IV diseaseMutant non-small cell lung cancerEGFR-mutant non-small cell lung cancerLines of therapySecond-line therapyStage IV diseaseKaplan-Meier curvesCell lung cancerGeneration EGFR-TKINon-Asian patientsT790M resistanceInstitution's IRBMedian PFSBrain metastasesComparison of subgroupsFree survivalLine therapyBaseline characteristicsEGFR therapyEGFR-TKIRetrospective study